Sugi Predict

Sugi Predict / Compounds / SCHEMBL1459005

SCHEMBL1459005

SCHEMBL1459005

O=Cc1c(F)cc(O)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CRHBP P24387 1/20 0.41
▸ CRHR2 Q13324 1/20 0.41
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ ERN1 O75460 5/20 0.35
▸ MIF P14174 1/20 0.34
▸ TTR P02766 2/20 0.33
▸ BACE1 P56817 1/20 0.33
▸ TAAR1 Q96RJ0 1/20 0.33
▸ CA12 O43570 1/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA9 Q16790 1/20 0.32
▸ ESR1 P03372 2/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ MDM4 O15151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL209239 0.84 HSD17B10 (0.50) HSD17B10CYP3A4HPGDCRHBPCRHR2
SCHEMBL604311 0.84 ERN1 (0.41) ERN1MIFBACE1TAAR1CA12
SCHEMBL6060504 0.78 ERN1 (0.42) HSD17B10CYP3A4KMT2AMEN1ALDH1A1
SCHEMBL2024626 0.78 ERN1 (0.46) HSD17B10CYP3A4HPGDCRHBPCRHR2
SCHEMBL83764 0.78 ERN1 (0.41) CYP3A4HPGDKMT2AMEN1ERN1
SCHEMBL9712527 0.78 ERN1 (0.42) KMT2AMEN1ALDH1A1TDP1ERN1
SCHEMBL29824002 0.78 ERN1 (0.42) KMT2AMEN1ALDH1A1TDP1ERN1
SCHEMBL27702448 0.77 ALDH1A1 (0.45) HSD17B10KMT2AMEN1ALDH1A1TDP1
SCHEMBL15543777 0.75 ALDH1A1 (0.37) HPGDKMT2AMEN1ALDH1A1TDP1
SCHEMBL18646094 0.75 ERN1 (0.40) CYP3A4ERN1MIFTAAR1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111777593-B Novel compounds as inhibitors of rearrangement kinase during transfection 南京天印健华医药科技有限公司 2024-07-23 — — CN disclosed
WO-2023198873-A1 DEUTERATED RORGAMMA/RORGAMMAT INVERSE AGONISTS IMMUNIC AG (DE) 2023-10-19 — — WO disclosed
CN-111777593-A Novel compounds as inhibitors of rearrangement kinase during transfection 南京天印健华医药科技有限公司 2020-10-16 — — CN disclosed
US-20150259327-A1 Chemical Compounds PFIZER LIMITED (GB) 2015-09-17 — — US disclosed
US-9067922-B2 Chemical compounds PFIZER LIMITED (GB) 2015-06-30 — — US disclosed
WO-2014170792-A1 SULFONAMIDE DERIVATIVES AS URAT-1 INHIBITORS PFIZER LIMITED (GB) 2014-10-23 — — WO disclosed
US-20140315878-A1 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2014-10-23 — — US disclosed
EP-2155747-B1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LTD (GB) 2012-10-24 — — EP disclosed
EP-2155747-B1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LTD (GB) 2012-10-24 — — EP disclosed
EP-2480529-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 — — EP disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 — — US disclosed
EP-1899296-B1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2010-11-17 — — EP disclosed
US-7812040-B2 such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders PFIZER INC. (US) 2010-10-12 — — US disclosed
CN-101855222-A Imidazol (1,2-A)pyridines and related compounds with activity at cannabinoid CB2 receptors GE HEALTHCARE LTD 2010-10-06 — — CN disclosed
EP-2155747-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS Acadia Pharmaceuticals Inc. (US) 2010-02-24 — — EP disclosed
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER INC. (US) 2009-05-21 — — US disclosed
WO-2008141249-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2008-11-20 — — WO disclosed
WO-2008141249-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2008-11-20 — — WO disclosed
EP-1899296-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2008-03-19 — — EP disclosed
WO-2006136924-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS HRH3, HRH4, HRH2 HSD17B10 1916/4885CYP3A4 1521/4885HPGD 1076/4885
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ORAI1, RYR2, CACNA1E HSD17B10 2598/4885CYP3A4 1339/4885HPGD 2285/4885
US-20150259327-A1 Chemical Compounds SULT2A1, SULT1A1, SULT1E1 HSD17B10 2398/4885CYP3A4 1604/4885HPGD 4483/4885
US-20140315878-A1 CHEMICAL COMPOUNDS SULT2A1, SULT1A1, SULT1E1 HSD17B10 2398/4885CYP3A4 1604/4885HPGD 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.